Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
03/2005
03/10/2005CA2537057A1 Cancer treatment with epothilones
03/10/2005CA2536912A1 Combination therapy for the treatment of ocular neovascular disorders
03/10/2005CA2536906A1 Compositions for treating pathologies that necessitate suppression of gastric acid secretion
03/10/2005CA2536466A1 Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
03/10/2005CA2536458A1 Composition comprising a pulmonary surfactant and a pde2 inhibitor
03/10/2005CA2536432A1 Combination therapy for glycaemic control
03/10/2005CA2535265A1 Compositions and methods for the treatment of disease associated with trp-p8 expression
03/10/2005CA2529027A1 D-amino acid peptides
03/10/2005CA2525374A1 Delivery of compounds with rehydrated blood cells
03/09/2005EP1512696A1 Amino acid sequences facilitating penetration of a substance of interest into cells and/or cell nuclei
03/09/2005EP1512670A1 Electrolytic reduced water, anti-cancer drug, and producing method and apparatus thereof
03/09/2005EP1512414A1 Hapten-carrier conjugates for treating and preventing nicotine addiction
03/09/2005EP1512413A2 Pharmaceutical combination containing a 4-quinazolineamine and another anti-neoplastic agent for the treatment of cancer
03/09/2005EP1512412A1 Method to identify anti-apoptotic compounds
03/09/2005EP1512410A1 Use of a composition for treating organ tissue injury caused by reperfusion of blood flow following a period of ischemia
03/09/2005EP1512016A1 Screening method and anti-tumor drug candidate obtained therefrom
03/09/2005EP1511864A2 Viral capsid assembly intermediates
03/09/2005EP1511853A2 Regulation of novel human asparagine-hydroxylases
03/09/2005EP1511759A1 Modulators and inhibitors of fibroblast growth factor receptor 5-polypeptides and gene expression thereof.
03/09/2005EP1511734A2 Compounds, compositions, and methods
03/09/2005EP1511721A2 Guanidino phenylalanin compounds used as urokinase inhibitors
03/09/2005EP1511719A1 Amide derivatives as inhibitors of the enzymatic activity of renin
03/09/2005EP1511537A2 Method of controlled ovarian hyperstimulation and pharmaceutical kit for use in such method
03/09/2005EP1511514A1 Fp receptor antagonists or pgf2 alpha antagonists for treating pathological conditions of the uterus
03/09/2005EP1511509A1 Compositions and methods for treating diabetes
03/09/2005EP1511505A2 Novel therapies and methods of screening for therapeutic compounds
03/09/2005EP1511501A1 A stable bicarbonate-based solution in a single container
03/09/2005EP1511500A2 Combination of anti-muscarinic agents and non-glucocorticoid steroids
03/09/2005EP1511497A1 Treatment of post-menopausal complaints in breast cancer patients which comprises tibolone and a serm
03/09/2005EP1511486A1 Use of dopamine partial agonists for the treatment of the restless legs syndrome and corresponding pharmaceutical preparation
03/09/2005EP1511484A1 Combination of a dpp iv inhibitor and a cardiovascular compound
03/09/2005EP1511483A2 Methods of treatment with lxr modulators
03/09/2005EP1511482A1 2-ureido-6-heteroaryl-3h-benzoimidazole-4-carboxylic acid derivatives and related compounds as gyrase and/or topoisomerase iv inhibitors for the treatment of bacterial infections
03/09/2005EP1511475A1 A herbal molecule as potential anti-leukemic drug
03/09/2005EP1511468A1 Nanoparticulate sterol formulations and sterol combinations
03/09/2005EP1511467A1 Nanoparticulate polycosanol formulations and novel polycosanol combinations
03/09/2005EP1511397A1 Dietary method for modulatng glucose metabolism and associated conditions and increasing longevity
03/09/2005EP1511393A1 A method of improving the growth performance of an animal
03/09/2005EP1448053A4 Proliferation and differentiation of stem cells using extracellular matrix and other molecules
03/09/2005EP1429798A4 Optimal compositions and methods thereof for treating hcv infections
03/09/2005EP1392354B1 Use of alpha-1 antichymotrypsin for the manufacture of a composition for treatment, prevention or diagnosis of poorly healing diabetic wounds
03/09/2005EP1303261B1 Self-emulsifying drug delivery systems for extremely water-insoluble, lipophilic drugs
03/09/2005EP1255552B1 Prostaglandin compositions for the treatment for male erectile dysfunction
03/09/2005EP1126849B1 Heterocyclic potassium channel inhibitors
03/09/2005EP0935471B1 Mononuclear phagocytes in therapeutic drug delivery
03/09/2005EP0848592B2 Antistress agents for aquatic animals
03/09/2005EP0673241B1 Use of a free radical quenching liposomal composition for the manufacture of a medicament for the treatment of inflammatory conditions
03/09/2005CN1592794A Cell culture system for synthesis of infectious hepatitis C virus
03/09/2005CN1592755A Anti-angiogenic peptides
03/09/2005CN1592704A Adsorbents and uses thereof
03/09/2005CN1592645A Combination therapy for treatment of autoimmune diseases using B cell depleting/immunoregulatory anti-body combination
03/09/2005CN1592643A Methods and apparatuses for assuring quality and safety of drug administration and medical products and kits
03/09/2005CN1592638A Promoters exhibiting endothelial cell specificity and methods of using same
03/09/2005CN1592637A Medicinal compositions
03/09/2005CN1592632A Combined use of VII polypeptides and factor VIII polypeptides
03/09/2005CN1592629A L-methionine as a stabilizer for NESP/EPO in hsa-free formulations
03/09/2005CN1592620A Treating and preventing method of disease relative to cardiac insulin resistance
03/09/2005CN1592616A GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity
03/09/2005CN1592614A Partial dopamine-d 2 receptor agonist plus serotonin and/oder noradrenaline inhibitor activity
03/09/2005CN1592609A Abuse-resistant opioid dosage form
03/09/2005CN1592577A Anthelmintic composition
03/09/2005CN1592576A Disruption of the prostaglandin E synthase 2 gene
03/09/2005CN1589908A Tenascin-C nucleic acid ligands
03/09/2005CN1589906A New oral formulation for 5-HT4 agonists or antagonists
03/09/2005CN1589905A Medical composition for treating desmosis and its use
03/09/2005CN1589904A Use of hemopoietic stem cell mobilizer in preparation of medicine for treating diabetes
03/09/2005CN1192107C 5S clavate alkyl gene separated from rhabdion streptomycete and its application in clavulanic acid production
03/09/2005CN1192102C Enzyme catalyzed therapeutic agents
03/09/2005CN1192035C Inhibitors of interleukin-1'beta' converting enzyme
03/09/2005CN1192028C Heterocyclic substituted aminoazacycles useful as central nervous system agents
03/09/2005CN1191862C Thermodynamic adaptive phased array system for activating thermosensitive liposomes in targeted drug delivery
03/09/2005CN1191858C Method for inhibiting brain tnmor growth
03/09/2005CN1191857C potentiation of anti-CD38-immunotoxin cytotoxicity
03/09/2005CN1191856C Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke
03/09/2005CN1191835C Pharmaceutical use of pyrimidyl nucleoside
03/09/2005CN1191832C Neovascularization promoters
03/09/2005CN1191826C Pharmaceutical formulation
03/08/2005US6864383 Ophthalmic compositions for treating ocular hypertension
03/08/2005US6864287 Cardiovascular disorders; hypotensive agents
03/08/2005US6864271 Synergistic combinations including N-acylated 4-hydroxyphenylamine derivatives
03/08/2005US6864264 1-adamantyl chalcones for the treatment of proliferative disorders
03/08/2005US6864262 Bladder disorders; incontinence; side effect reduction
03/08/2005US6864243 Method for treating retinal degeneration with purinergic receptor agonists
03/08/2005US6864242 Mixtures of arginine, glutamine, proline and acyclic carboxy amines selected from leucine, isoleucine or valine, used as nutraceuticals for prophylaxis of metabolic disorders
03/08/2005US6864227 Artery-and vein-specific proteins and uses therefor
03/08/2005US6864070 Polypeptide for use in the treatment of vision defects and psychological disorders
03/08/2005US6863904 Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects
03/08/2005US6863901 Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
03/08/2005US6863898 Method and composition for treating hairy hoof warts
03/08/2005US6863885 Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
03/08/2005CA2351848C Method for increasing pet activity
03/08/2005CA2239952C Surface-stabilised pharmaceutical preparation for application on the skin
03/08/2005CA2105230C Pharmaceutical or cosmetic composition containing peroxidase associated with an anti-oxygen singlet agent
03/03/2005WO2005019417A2 Bacterial strains, compositions including same and probiotic use thereof
03/03/2005WO2005019157A1 Choline esters useful for the treatment of cognitive dysfunctions and enhancement of memory, learning and cognition
03/03/2005WO2005019151A1 Ppar modulators
03/03/2005WO2005018677A2 Use of combination of an epidermal growth factor receptor kinase inhibitor and cytotoxic agents for treatment and inhibition of cancer
03/03/2005WO2005018676A1 The combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression
03/03/2005WO2005018670A1 Pharmaceutical composition comprising an alpha2delta ligand and an opioid receptor antagonist for the prevention and treatment of addiction in a mammal
03/03/2005WO2005018668A1 Method of inducing immune tolerance
1 ... 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 ... 1151